Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit
By Amanda Lee
Sinopharm Group's shares fell by their most in more than six months in early trade after the Chinese state-owned pharmaceutical giant's quarterly profit fell amid higher operating costs and impairments.
Shares were down 6.4% at 20.45 Hong Kong dollars ($2.61) early Monday, taking them into the red for the year.
Sinopharm said ahead of trading that first-quarter profit dropped 11% from a year earlier to 1.42 billion yuan ($196 million). A 1.2% rise in total operating revenue was offset by a 1.5% rise in total operating cost, while credit impairment losses expanded 15% on year.
The company separately said its board had approved a plan to raise CNY30.0 billion via the issuance of corporate debt to repay loans and matured debt, replenish working capital and fund project construction, saying the moves would help trim financing costs and improve debt structure.
The issuance, which is subject to approval by shareholders and regulators, will comprise CNY25.0 billion in short-term debt with a one-year term and CNY5.0 billion in debt with a term of up to 10 years.
Write to Amanda Lee at amanda.lee@wsj.com
(END) Dow Jones Newswires
April 28, 2024 23:46 ET (03:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending